ABSTRACT
Objective To study the clinical effect of Hin ceruminous injection after uterine lapa-roscopy combined operation in treatment of salpinx obstructive infertility ,which was done under the guidance of color Doppler ultrasound . [ Methods] A series of 160 salpinx obstructive infertility patients were in-cluded and randomly divided into the treatment group ( n=80 , treated with Hin ceruminous injection under the guidance of Color ultrasound 3-7 days after the first Menstrual cycle following hysteroscopy operation ) and the control group ( n=80 , treated by expectant method ) .The pregnancies were compared in the two groups 1 year after operation .The unpregnant patients were given Ioversol check 3 to 7 days after menstrua-tion clean to compare patency conditions of Fallopian tube between the two groups . [ Results] One year after operation the normal intrauterine pregnancy rate was 68.75%,which was higher than 51.25% in the control group .The difference was significant between the two groups (χ2 =5 .104 , P =0 .024 ) .Ectopic pregnancy rates were compared between the two groups and the difference was not significant (P>0.05). The patency rate of bilateral fallopian tubes in unpregnant patients of the observation group was 40 .9%, which was remarkably higher than 14.2%in the control group (P<0.05).And the incidence of impotency was 9.1%,which was markedly lower than 42.8%in the control group(P<0.01).And comparison of the total patency rates showed that the difference between the two groups was not significant ( P>0 .05 ) . [ Conclusion] Hin ceruminous injection after Hysteroscopy operation in treatment of salpinx obstructive infertility is effective and safe .
ABSTRACT
<p><b>OBJECTIVE</b>To investigate chronic hepatitis B (CHB) patients infected with the antiviral-resistant rtA181 mutation hepatitis B virus (HBV) who have been unresponsive to general therapy to determine the effects of individualized therapy.</p><p><b>METHODS</b>Fifty-four patients with confirmed rtA181 mutation and who experienced virological breakthrough during nucleus(t)ide analogue (NUC) treatment were enrolled in this prospective cohort study. Their serum levels of HBV DNA, hepatitis B surface antigen (HBsAg), and alanine transaminase (ALT) were tested. Each patient was genotyped by pyrosequencing for 10 mutation sites in the HBV P gene that have been previously correlated to NUC efficacy. Each patient's antiviral therapy and response history was analyzed in regard to their particular mutation pattern. The serological index was determined for carriers of the rtA181T/V mutation. The secondary individualized treatment included adding/switching to entecavir (ETV; group A) or adding telbivudine (LdT; group B) upon confirmation of drug resistance. Effect of individualized treatment was analyzed by T test and Mann-Whitney U test for continuous variables with normal or skewed distributions, respectively. Categorical variables were analyzed by the Chi-squared ( x² ) or Fisher's exact tests.</p><p><b>RESULTS</b>The rtA181T mutation was found in 64.8% (35/54) of patients with rtA181 mutation HBV. The most frequent previously administered medications were adefovir dipivoxil (ADV) and lamivudine (LAM). Multi-site rtA181 mutations occurred more frequently in the patients with multi-NUCs history (57.6%) than in those with single NUCs history (28.6%) (x²=4.342, P less than 0.05). Serum HBV DNA level at virological breakthrough was lower than that at baseline of the first antiviral treatment (5.66+/-1.01 vs. 6.75+/-0.81 log10 copies/ml; t=-4.210, P less than 0.01). The serum HBsAg level was higher in carriers of the rtA181T mutation than in carriers of the rtA181V mutation (3.80+/-0.45 vs. 3.46+/-0.60 log10 IU/ml; t=2.109, P less than 0.05). In patients with serum HBV DNA more than or equal to 6 log10 copies/ml at viral breakthrough, 100% (8/8) of patients in the secondary treatment group A and 75% (3/4) patients in the secondary treatment group B exhibited virological response at week 24 after intervention. Undetectable HBV DNA was achieved in three patients of group A and one patient of group B. In patients with serum HBV DNA less than 6 log10 copies/ml at viral breakthrough, 100% (14/14) of patients in group A and 71.4% (5/7) of patients in group B exhibited biological response at week 24 after intervention. The serum HBV DNA level decreased to undetectable levels in 12 patients of group A and four patients of group B.</p><p><b>CONCLUSION</b>The rtA181 mutation pattern correlates with previous antiviral therapy response. In addition, multi-site rtA181 mutations occur more frequently in patients with a history of multi-NUCs therapy. Adding or switching rtA181 carriers to ETV produces a more robust virological suppression than adding LdT.</p>
Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Young Adult , Antiviral Agents , Therapeutic Uses , Drug Resistance, Viral , Genetics , Hepatitis B virus , Genetics , Hepatitis B, Chronic , Drug Therapy , Virology , Membrane Proteins , Genetics , Point Mutation , Prospective Studies , Retrospective StudiesABSTRACT
<p><b>OBJECTIVE</b>To study the chemical constituents in bark of Larix olgensis var. koreana.</p><p><b>METHOD</b>The compounds were isolated with silica gel column chromatography and their structures were elucidated on the basis of spectral analysis (IR, EI-MS, 1H-NMR, 13C-NMR).</p><p><b>RESULT</b>Eight compounds were isolated and identified as isopimaric acid (I), beta-sitosterol (II), 24R,5alpha-stigmast-3,6-dione (III), larixol (IV), ferulic acid (V), lariciresinol (VI), secroisolariciresinol (VII) and isolariciresinol (VIII).</p><p><b>CONCLUSION</b>All the compounds were isolated from this plant for the first time.</p>